🇺🇸 FDA
Pipeline program

Dinutuximab

ANBL1821

Phase 2 mab active

Quick answer

Dinutuximab for High Risk Neuroblastoma is a Phase 2 program (mab) at Children's Hospital of Fudan University with 1 ClinicalTrials.gov record(s).

Program details

Company
Children's Hospital of Fudan University
Indication
High Risk Neuroblastoma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials